OBJECTIVES: To investigate temporal changes in the risk of non-Hodgkin lymphoma (NHL) and estimate NHL incidence in risk groups and the prognostic role of these risks and current, nadir and time-weighted average CD4 cell count. METHODS: Secular trends in time from HIV seroconversion to an NHL diagnosis was estimated using Cox models from data pooled from the 22 seroconverter cohorts in the CASCADE collaboration for three periods (pre-1997, 1997-1998, 1999-2002), adjusting for age at seroconversion, exposure category and sex. RESULTS: Of 7103 seroconverters, 129 developed NHL. Compared with pre-1997, there was little reduction in NHL risk in 1997-1998 [relative risk (RR), 0.66; 95% confidence interval (CI), 0.37-1.17] then a substantial reduction in 1999-2002 (RR, 0.25, 95% CI, 0.12-0.53). Compared with individuals with CD4 cell count > 350 x 10 cells/l, the RR of NHL increased to 1.9 (95% CI, 1.0-3.6), 1.4 (95% CI, 0.6-3.5) and 11.2 (95% CI, 6.3-20.0) at CD4 cell counts 200-349, 100-199 and < 100 x 10 cells/l, respectively. There was no evidence that nadir (P = 0.41) or time-weighted average CD4 cell count (P = 0.38) contributed further to predicting NHL risk or were better predictors than current CD4 cell count. For individuals with CD4 cell count > 350 x 10 cells/l pre-HAART, an NHL incidence of 1.8 and 0.4/1000 person-years was estimated for those at highest and lowest risk, respectively, when classified by age and exposure category. CONCLUSION: There appears to be no justification for initiating HAART at CD4 cell counts > 100 x 10 cells/l based specifically on concerns over NHL. The risk of NHL is, however, greatly increased at lower CD4 cell counts.
OBJECTIVES: To investigate temporal changes in the risk of non-Hodgkin lymphoma (NHL) and estimate NHL incidence in risk groups and the prognostic role of these risks and current, nadir and time-weighted average CD4 cell count. METHODS: Secular trends in time from HIV seroconversion to an NHL diagnosis was estimated using Cox models from data pooled from the 22 seroconverter cohorts in the CASCADE collaboration for three periods (pre-1997, 1997-1998, 1999-2002), adjusting for age at seroconversion, exposure category and sex. RESULTS: Of 7103 seroconverters, 129 developed NHL. Compared with pre-1997, there was little reduction in NHL risk in 1997-1998 [relative risk (RR), 0.66; 95% confidence interval (CI), 0.37-1.17] then a substantial reduction in 1999-2002 (RR, 0.25, 95% CI, 0.12-0.53). Compared with individuals with CD4 cell count > 350 x 10 cells/l, the RR of NHL increased to 1.9 (95% CI, 1.0-3.6), 1.4 (95% CI, 0.6-3.5) and 11.2 (95% CI, 6.3-20.0) at CD4 cell counts 200-349, 100-199 and < 100 x 10 cells/l, respectively. There was no evidence that nadir (P = 0.41) or time-weighted average CD4 cell count (P = 0.38) contributed further to predicting NHL risk or were better predictors than current CD4 cell count. For individuals with CD4 cell count > 350 x 10 cells/l pre-HAART, an NHL incidence of 1.8 and 0.4/1000 person-years was estimated for those at highest and lowest risk, respectively, when classified by age and exposure category. CONCLUSION: There appears to be no justification for initiating HAART at CD4 cell counts > 100 x 10 cells/l based specifically on concerns over NHL. The risk of NHL is, however, greatly increased at lower CD4 cell counts.
Authors: Sharon Pipkin; Susan Scheer; Ijeoma Okeigwe; Sandra Schwarcz; David H Harris; Nancy A Hessol Journal: AIDS Date: 2011-02-20 Impact factor: 4.177
Authors: Yi Lin; Michael P Gustafson; Peggy A Bulur; Dennis A Gastineau; Thomas E Witzig; Allan B Dietz Journal: Blood Date: 2010-11-09 Impact factor: 22.113
Authors: H Byakwaga; K Petoumenos; J Ananworanich; F Zhang; M A Boyd; T Sirisanthana; P C K Li; C Lee; C V Mean; V Saphonn; S F S Omar; S Pujari; P Phanuphak; P L Lim; N Kumarasamy; Y M A Chen; T P Merati; S Sungkanuparph; R Ditangco; S Oka; G Tau; J Zhou; M G Law; S Emery Journal: J Int Assoc Provid AIDS Care Date: 2013-02-19
Authors: Mark Bower; Martin Fisher; Teresa Hill; Iain Reeves; John Walsh; Chloe Orkin; Andrew N Phillips; Loveleen Bansi; Richard Gilson; Philippa Easterbrook; Margaret Johnson; Brian Gazzard; Clifford Leen; Deenan Pillay; Achim Schwenk; Jane Anderson; Kholoud Porter; Mark Gompels; Caroline A Sabin Journal: Haematologica Date: 2009-03-31 Impact factor: 9.941
Authors: Gregory D Huhn; Sheila Badri; Sonia Vibhakar; Frank Tverdek; Christopher Crank; Ronald Lubelchek; Blake Max; David Simon; Beverly Sha; Oluwatoyin Adeyemi; Patricia Herrera; Allan Tenorio; Harold Kessler; David Barker Journal: AIDS Res Ther Date: 2010-12-14 Impact factor: 2.250
Authors: Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Gypsyamber D'Souza; Kelly A Gebo; M John Gill; Surbhi Grover; Michael A Horberg; Jun Li; W Christopher Mathews; Angel M Mayor; Lesley S Park; Charles S Rabkin; Kate Salters; Amy C Justice; Richard D Moore; Eric A Engels; Michael J Silverberg; Robert Dubrow Journal: Lancet HIV Date: 2019-02-27 Impact factor: 16.070